On Tuesday, TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device ...
Truist analyst Jailendra Singh lowered the firm’s price target on Icon (ICLR) to $295 from $363 and keeps a Buy rating on the shares. With the Q4 and 2025 outlook now essentially de-risked, Truist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback